Up-regulation of flotillin-2 is associated with renal cell carcinoma progression

Tumor Biology

Volumn 35, Issue 10, 2014, Pages 10479-10486

  Yan, Yang ^a   Yang, Feng Qiang ^a   Zhang, Hai Min ^a   Che, Jianping ^a   Zheng, Jun Hua ^a  

^a TONGJI UNIVERSITY   (China)

Author keywords

FLOT2; Invasion; Migration; Proliferation; Renal cell carcinoma

Indexed keywords

FLOTILLINS; MEMBRANE PROTEIN; SMALL INTERFERING RNA; TUMOR MARKER;

AGED; BIOSYNTHESIS; DISEASE COURSE; FEMALE; GENETIC TRANSFECTION; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

AGED; BLOTTING, WESTERN; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84922393633     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2343-9     Document Type: Article

References (17)

1. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet. 2009; 373(9669): 1119-32.
2. Yang FQ, Yang FP, Li W, et al. Foxl1 inhibits tumor invasion and predicts outcome in human renal cancer. Int J Cli Exp Pathol. 2014; 7(1): 110.
3. Ljungberg B, Cowan NC, Hanbury DC, et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol. 2010; 58(3): 398-406.
4. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med. 2005; 353(23): 2477-90.
5. Hollingsworth JM, Miller DC, Daignault S, et al. Five-year survival after surgical treatment for kidney cancer. Cancer. 2007; 109(9): 1763-8.
6. Babuke T, Tikkanen R. Dissecting the molecular function of reggie/ flotillin proteins. Eur J Cell Biol. 2007; 86(9): 525-32.
7. Staubach S, Hanisch FG. Lipid rafts: signaling and sorting platforms of cells and their roles in cancer. Expert Rev Proteome. 2011; 8(2): 263-77.
8. Márquez DC, Chen HW, Curran EM, et al. Estrogen receptors in membrane lipid rafts and signal transduction in breast cancer. Mol Cell Endocrinol. 2006; 246(1): 91-100.
9. Banning A, Kurrle N, Meister M, et al. Flotillins in receptor tyrosine kinase signaling and cancer. Cells. 2014; 3(1): 129-49.
10. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000; 406(6797): 747-52.
11. Hazarika P, McCartyMF, Prieto VG, et al. Up-regulation of Flotillin-2 is associated with melanoma progression and modulates expression of the thrombin receptor protease activated receptor 1. Cancer Res. 2004; 64(20): 7361-9.
12. Berger T, Ueda T, Arpaia E, et al. Flotillin-2 deficiency leads to reduced lung metastases in a mouse breast cancer model. Oncogene, 2012.
13. Wang X, Yang Q, Guo L, et al. Flotillin-2 is associated with breast cancer progression and poor survival outcomes. J Transl Med. 2013; 11(1): 190.
14. Cheng YX, Hu M, Chen L, et al. The mechanism of lipid raft mediating chemoresistance of cervical cancer. Saudi Med J. 2012; 33(5): 508-14.
15. George KS, Wu S. Lipid raft: a floating island of death or survival. Toxicol Appl Pharmacol. 2012; 259(3): 311-9.
16. Ji H, Greening DW, Barnes TW, et al. Proteome profiling of exosomes derived from human primary and metastatic colorectal cancer cells reveal differential expression of key metastatic factors and signal transduction components. Proteomics. 2013; 13(10-11): 1672-86.
17. Cao K, Xie D, Cao P, et al. SiRNA-mediated flotillin-2 (Flot2) downregulation inhibits cell proliferation, migration, and invasion in gastric carcinoma cells. Oncol Res Featuring Preclinical Clin Cancer Ther. 2014; 21(5): 271-9.